93 results on '"Lefebvre, Patrick"'
Search Results
2. Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis
3. Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States
4. Real-world clinical management of individuals with Rett syndrome: a physician survey
5. Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma
6. Ischemic stroke and systemic embolism among patients with non-valvular atrial fibrillation who abandon oral anticoagulant therapy
7. Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia
8. Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance
9. Continuity of care among patients newly initiated on second-generation oral or long-acting injectable antipsychotics during a schizophrenia-related inpatient stay
10. Treatment persistence among bio-naïve patients with Crohn's disease initiated on ustekinumab or adalimumab
11. Author’s Response to Letter to the Editor - Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613–627
12. Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey
13. Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States
14. Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey
15. National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States
16. Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer
17. Development and evaluation of a predictive algorithm for unsatisfactory response among patients with pulmonary arterial hypertension using health insurance claims data
18. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab
19. Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspective
20. The societal economic value of COVID-19 vaccines in the United States
21. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States
22. Prevalence of post-traumatic stress disorder in the United States: a systematic literature review
23. Treatment patterns among adults with attention-deficit/hyperactivity disorder in the United States: a retrospective claims study
24. Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiaries
25. Development and validation of a claims-based model to identify patients at risk of chronic thromboembolic pulmonary hypertension following acute pulmonary embolism
26. Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax
27. Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population
28. Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer
29. Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study
30. Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data
31. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate
32. Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes
33. Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population
34. Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization
35. Healthcare costs of patients with cancer stratified by Khorana score risk levels
36. Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
37. Health care resource use, short-term disability days, and costs associated with states of persistence on antidepressant lines of therapy
38. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder
39. Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
40. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia
41. Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US
42. Burden of Crohn’s disease in the United States: long-term healthcare and work-loss related costs
43. An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus
44. Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population
45. Use of home health and other healthcare delivery pathways among privately insured patients with and without treatment-resistant depression
46. Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer
47. Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE clinical trial
48. Development of risk models for major adverse chronic renal outcomes among patients with type 2 diabetes mellitus using insurance claims: a retrospective observational study
49. Adherence to heart failure management medications following cardiac resynchronization therapy
50. Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.